Intelligent Bio Solutions Files 8-K on Financials
Ticker: INBS · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1725430
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
IBSI filed an 8-K on Feb 6, 2025, detailing financial results and exhibits.
AI Summary
Intelligent Bio Solutions Inc. filed an 8-K on February 6, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The company, formerly known as GBS Inc., is incorporated in Delaware and headquartered in New York.
Why It Matters
This filing provides investors with updated financial information and operational results for Intelligent Bio Solutions Inc., crucial for assessing the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not indicate any immediate material changes or risks.
Key Players & Entities
- Intelligent Bio Solutions Inc. (company) — Registrant
- GBS Inc. (company) — Former company name
- Glucose Biosensor Systems (Greater China) Holdings, Inc. (company) — Former company name
- February 6, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition, as well as Financial Statements and Exhibits of Intelligent Bio Solutions Inc.
When was this 8-K report filed?
This 8-K report was filed on February 6, 2025.
What were the previous names of Intelligent Bio Solutions Inc.?
Intelligent Bio Solutions Inc. was formerly known as GBS Inc. and Glucose Biosensor Systems (Greater China) Holdings, Inc.
In which state is Intelligent Bio Solutions Inc. incorporated?
Intelligent Bio Solutions Inc. is incorporated in Delaware.
What is the principal executive office address for Intelligent Bio Solutions Inc.?
The principal executive office address for Intelligent Bio Solutions Inc. is 135 West 41st Street, 5th Floor, New York, NY 10036.
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2025-02-06 17:16:05
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value INBS The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex99-1.htm (EX-99.1) — 22KB
- ex99-1_001.jpg (GRAPHIC) — 32KB
- ex99-1_002.jpg (GRAPHIC) — 47KB
- 0001493152-25-005244.txt ( ) — 347KB
- inbs-20250206.xsd (EX-101.SCH) — 3KB
- inbs-20250206_lab.xml (EX-101.LAB) — 33KB
- inbs-20250206_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 6, 2025 INTELLIGENT BIO SOLUTIONS INC. By: /s/ Spiro Sakiris Name: Spiro Sakiris Title: Chief Financial Officer